معرفی
Yves Gaudin is a virologist and Director of Research at the Institute for Integrative Biology of the Cell (I2BC), a joint research unit of Université Paris-Saclay, CEA, and CNRS. He also serves as Deputy Director of the Graduate School Life, Sciences and Health at Université Paris-Saclay and participates in the Maladies infectieuses émergentes working group at the French Agency for Research on AIDS and Viral Hepatitis.
Research Focus
Dr. Gaudin has dedicated over 30 years to studying rhabdoviridae viruses, particularly rabies and vesiculoviruses. His research centers on viral cell entry mechanisms and the formation of viral factories within infected cells. He pioneered the discovery that viral factories form through liquid-liquid phase separation, a finding published in Nature Communications in 2017 that earned his team the Bettencourt Coups d'Élan prize in 2019.
His work extends to biotechnological applications, particularly modifying the glycoprotein G of vesicular stomatitis virus (VSV) for targeted cancer therapy. This innovative approach aims to specifically deliver therapeutic viruses to tumor cells while sparing healthy tissue.
Scientific Recognition
- Bettencourt Coups d'Élan prize (2019) for discovering viral factories form through liquid-liquid phase separation
- Published two significant papers in Science (2006, 2007) on VSV glycoprotein structures
- Holds two patents (filed since 2018) on VSV glycoprotein retargeting applications
Professional Activities
Dr. Gaudin leads a research team of approximately a dozen scientists at I2BC. His administrative roles include presiding over Section 20 of the CNRS (Molecular and structural biology, biochemistry) from 2016-2021 and serving as Deputy Director of the Graduate School Life Sciences and Health since May 2020. He has taught at École Polytechnique for 12 years and maintains active collaborations with institutions including Institut Curie.
Research Infrastructure
His laboratory at I2BC receives funding from multiple sources including CNRS' programme de prématuration, Association pour la recherche sur le cancer (ARC), Banque publique d'investissement (BPI), and an American start-up. The team is actively developing glycoprotein technology with potential applications in targeted cancer therapy.
